Loading
Life sciences · Journal article
BMC Cardiovascular Disorders · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
To compare the associations and incremental discriminatory ability of 16 alternative metabolic markers with incident cardiometabolic multimorbidity (CMM) and explore potential mediating pathways. Using the CHARLS cohort ( n = 7,646), we evaluated 16 markers. Primary analyses comprised Cox regression, competing-risk models, and ROC/IDI/NRI assessments of incremental discrimination. XGBoost, qgcomp, and SEM served as secondary/exploratory analyses of feature importance, mixture effects, and mediation pathways. During follow-up, 633 participants developed CMM. All markers were significantly associated with CMM in quartile analyses; CVAI showed the strongest association (Q4 vs. Q1 HR: 5.15, 95% CI: 3.52–7.54). TyG-WC provided the greatest incremental improvement in discrimination (IDI = 0.026, NRI = 0.255, P < 0.001). Composite insulin resistance (IR) and atherogenic lipid indices accounted for 87.8% of the joint risk weight. SEM revealed a suppression pattern: biochemical IR statistically accounted for the association between structural (anthropometric) adiposity and CMM (indirect effect: 0.34, P < 0.001; mediation proportion: 121.9%, reflecting inconsistent mediation rather than complete mediation), while the direct effect of structural adiposity was negative and non-significant ( P > 0.05). Integrating biochemical and anthropometric markers (particularly TyG-WC) improves CMM risk stratification, although the incremental gains were modest and require external validation before clinical implementation. The association between structural adiposity and CMM was statistically accounted for by biochemical IR; in exploratory SEM analyses, structural obesity without metabolic dysfunction was not independently associated with CMM in this cohort. Whether this reflects a metabolically healthy phenotype warrants further study. Not applicable.